• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

雷帕霉素与顺铂联合应用对人宫颈癌Hela细胞的影响。

Effect of combination of rapamycin and cisplatin on human cervical carcinoma Hela cells.

作者信息

Han Lu, Wu Jie-Ling, Yang Li-Xiao

机构信息

Dalian Obstetrics and Gynecology Hospital, Dalian, Liaoning, China.

出版信息

Contemp Oncol (Pozn). 2012;16(6):512-5. doi: 10.5114/wo.2012.32483. Epub 2013 Jan 4.

DOI:10.5114/wo.2012.32483
PMID:23788937
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3687477/
Abstract

AIM OF THE STUDY

To evaluate the effect of combined use of rapamycin and cisplatin against Hela cells in vitro.

MATERIAL AND METHODS

The inhibitory effects of rapamycin and cisplatin, used alone or combination, on the proliferation of Hela cell were measured with MTT assay and median-effect plot analysis.

RESULTS

Combined use of rapamycin and cisplatin significantly improved the chemotherapeutic effect against Hela cells. The inhibitory rates were dose-dependent. Rapamycin and cisplatin showed synergistic effects in the chemotherapy of Hela cells (q > 1.15, King's formula).

CONCLUSIONS

Combined use of rapamycin and cisplatin significantly improves the chemotherapeutic effect against Hela cells.

摘要

研究目的

评估雷帕霉素和顺铂联合使用对体外培养的人宫颈癌HeLa细胞的作用。

材料与方法

采用MTT法和中位效应图分析法，检测雷帕霉素和顺铂单独及联合使用对HeLa细胞增殖的抑制作用。

结果

雷帕霉素和顺铂联合使用显著提高了对HeLa细胞的化疗效果。抑制率呈剂量依赖性。雷帕霉素和顺铂在HeLa细胞化疗中显示出协同作用（q>1.15，金氏公式）。

结论

雷帕霉素和顺铂联合使用显著提高了对HeLa细胞的化疗效果。

相似文献

1
Effect of combination of rapamycin and cisplatin on human cervical carcinoma Hela cells.雷帕霉素与顺铂联合应用对人宫颈癌Hela细胞的影响。
Contemp Oncol (Pozn). 2012;16(6):512-5. doi: 10.5114/wo.2012.32483. Epub 2013 Jan 4.
2
[Effect of chemotherapy with cisplatin and rapamycin against Hep-2 cells in vitro].顺铂与雷帕霉素联合化疗对体外培养的 Hep-2 细胞的作用
Nan Fang Yi Ke Da Xue Xue Bao. 2008 Oct;28(10):1838-41.
3
Synergistic effect of rapamycin and cisplatin in endometrial cancer cells.雷帕霉素和顺铂对子宫内膜癌细胞的协同作用。
Cancer. 2009 Sep 1;115(17):3887-96. doi: 10.1002/cncr.24431.
4
Intervention effects of nedaplatin and cisplatin on proliferation and apoptosis of human tumour cells in vitro.奈达铂和顺铂对人肿瘤细胞体外增殖和凋亡的干预作用
Asian Pac J Cancer Prev. 2012;13(9):4531-6. doi: 10.7314/apjcp.2012.13.9.4531.
5
The chemosensitizing effect of aqueous extract of sweet fennel on cisplatin treated HeLa cells.甜茴香水提取物对顺铂处理的HeLa细胞的化学增敏作用。
Clin Exp Obstet Gynecol. 2016;43(3):358-64.
6
FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.FOXO3a 的重新激活介导了雷帕霉素和顺铂在口腔鳞状细胞癌细胞中的协同细胞毒性作用。
Toxicol Appl Pharmacol. 2011 Feb 15;251(1):8-15. doi: 10.1016/j.taap.2010.11.007. Epub 2010 Nov 16.
7
Mifepristone sensitizing cisplatin for cervical adenocarcinoma HeLa cell sensitivity to chemotherapy and its mechanism.米非司酮使顺铂对宫颈腺癌HeLa细胞的化疗敏感性增强及其机制。
Eur J Gynaecol Oncol. 2013;34(2):142-7.
8
Synergistic anticancer activity of 5-aminolevulinic acid photodynamic therapy in combination with low-dose cisplatin on Hela cells.5-氨基酮戊酸光动力疗法联合低剂量顺铂对Hela细胞的协同抗癌活性
Asian Pac J Cancer Prev. 2013;14(5):3023-8. doi: 10.7314/apjcp.2013.14.5.3023.
9
Synergistic anticancer activity of Thiazolo[5,4-b]quinoline derivative D3CLP in combination with cisplatin in human cervical cancer cells.噻唑并[5,4-b]喹啉衍生物 D3CLP 与顺铂联合在人宫颈癌中的协同抗癌活性。
Anticancer Res. 2012 Dec;32(12):5159-65.
10
Combined antitumor effects of bee venom and cisplatin on human cervical and laryngeal carcinoma cells and their drug resistant sublines.蜂毒和顺铂对人宫颈癌和喉癌细胞及其耐药亚系的联合抗肿瘤作用。
J Appl Toxicol. 2014 Dec;34(12):1332-41. doi: 10.1002/jat.2959.

引用本文的文献

1
Engineering Self-Assembled Nanomedicines Composed of Clinically Approved Medicines for Enhanced Tumor Nanotherapy.工程化由临床批准药物组成的自组装纳米药物用于增强肿瘤纳米治疗
Nanomaterials (Basel). 2023 Sep 5;13(18):2499. doi: 10.3390/nano13182499.
2
The role of RICTOR amplification in targeted therapy and drug resistance.RICTOR 扩增在靶向治疗和耐药性中的作用。
Mol Med. 2020 Feb 10;26(1):20. doi: 10.1186/s10020-020-0146-6.
3
d-limonene exhibits antitumor activity by inducing autophagy and apoptosis in lung cancer.d-柠檬烯通过诱导肺癌细胞自噬和凋亡发挥抗肿瘤活性。
Onco Targets Ther. 2018 Apr 4;11:1833-1847. doi: 10.2147/OTT.S155716. eCollection 2018.
4
Expression proteomics study to determine metallodrug targets and optimal drug combinations.表达蛋白质组学研究确定金属药物靶点和最佳药物组合。
Sci Rep. 2017 May 8;7(1):1590. doi: 10.1038/s41598-017-01643-1.
5
An overview of rapamycin: from discovery to future perspectives.雷帕霉素综述：从发现到未来展望
J Ind Microbiol Biotechnol. 2017 May;44(4-5):537-553. doi: 10.1007/s10295-016-1834-7. Epub 2016 Sep 9.
6
Radiation enhancing effects of sanazole and gemcitabine in hypoxic breast and cervical cancer cells in vitro.沙那唑与吉西他滨对体外低氧乳腺癌和宫颈癌细胞的辐射增强作用。
Contemp Oncol (Pozn). 2015;19(3):236-40. doi: 10.5114/wo.2015.51820. Epub 2015 Jun 2.

本文引用的文献

1
Synergistic effect of rapamycin and cisplatin in endometrial cancer cells.雷帕霉素和顺铂对子宫内膜癌细胞的协同作用。
Cancer. 2009 Sep 1;115(17):3887-96. doi: 10.1002/cncr.24431.
2
Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination.雷帕霉素在体外对原发性慢性淋巴细胞白血病细胞显示出抗癌活性，无论是作为单一药物还是联合用药。
Leuk Lymphoma. 2008 Dec;49(12):2333-43. doi: 10.1080/10428190802475295.
3
A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.低剂量干扰素-α-2A、沙利度胺联合吉西他滨及卡培他滨用于进展期转移性肾细胞癌患者的I期临床试验。
Cancer Chemother Pharmacol. 2008 May;61(6):1069-73. doi: 10.1007/s00280-007-0568-7. Epub 2007 Aug 14.
4
Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma.雷帕霉素靶蛋白（mTOR）抑制在大鼠肝细胞癌模型中的血管重塑及抗肿瘤作用
J Hepatol. 2007 May;46(5):840-8. doi: 10.1016/j.jhep.2006.11.021. Epub 2007 Jan 17.
5
Current development of mTOR inhibitors as anticancer agents.mTOR抑制剂作为抗癌药物的当前进展。
Nat Rev Drug Discov. 2006 Aug;5(8):671-88. doi: 10.1038/nrd2062.
6
Inhibition of corneal neovascularization by rapamycin.雷帕霉素对角膜新生血管形成的抑制作用。
Exp Mol Med. 2006 Apr 30;38(2):173-9. doi: 10.1038/emm.2006.21.
7
Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer.人类乳腺癌中PDK-1/AKT通路磷酸化及激活水平升高。
Br J Cancer. 2005 Dec 12;93(12):1372-81. doi: 10.1038/sj.bjc.6602862.
8
Akt-regulated pathways in prostate cancer.前列腺癌中Akt调节的信号通路。
Oncogene. 2005 Nov 14;24(50):7465-74. doi: 10.1038/sj.onc.1209096.
9
Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.抑制磷脂酰肌醇3-激酶/蛋白激酶B/雷帕霉素哺乳动物靶标信号通路而非丝裂原活化蛋白激酶/细胞外信号调节激酶信号通路，可减弱层粘连蛋白介导的小细胞肺癌细胞存活以及对甲磺酸伊马替尼或化疗的耐药性。
Cancer Res. 2005 Sep 15;65(18):8423-32. doi: 10.1158/0008-5472.CAN-05-0058.
10
Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.雷帕霉素靶蛋白抑制剂克服肺癌顺铂耐药性的研究
Mol Cancer. 2005 Jul 20;4(1):25. doi: 10.1186/1476-4598-4-25.